Three injections versus two changes behavior in ways traditional analysis doesn't capture.
Across the world's clinics, children have long endured more needle sticks than necessary — not for lack of science, but for lack of a shared language to measure what combination vaccines are truly worth. PATH and the World Health Organization have answered this gap with a structured checklist tool that expands the lens of vaccine evaluation beyond disease prevention to capture the human and logistical value of fewer injections. Published in the journal Vaccine and refined through broad expert consultation, the framework introduces a traffic-light system to prioritize what matters most when assessing whether a new combination vaccine deserves development and adoption. It is, at its core, an attempt to make visible the value that has always existed but never been counted.
- Children in routine immunization programs still receive multiple separate injections when combination vaccines could reduce that burden — a solvable problem stalled by inadequate evaluation tools.
- Traditional cost-benefit analyses ignore critical real-world effects: parental hesitancy drops when needle counts fall, and coverage improves, yet none of this registers in standard frameworks.
- PATH and WHO conducted a systematic review and convened health economists and policy experts to identify the 'value drivers' that combination vaccines actually deliver — from reduced clinic burden to improved schedule completion.
- A traffic-light classification system now ranks these drivers by how measurable, policy-relevant, and impactful they are, exposing not just what we can assess but where critical research gaps remain.
- The checklist, published in Vaccine after a June 2025 expert convening, is being piloted on specific vaccines in development — with the ambition of giving manufacturers clear targets and helping stretched immunization programs allocate resources wisely.
In clinics around the world, children arriving for routine immunizations often receive multiple injections when a single combination vaccine could provide the same protection. Two combination vaccines — one for measles and rubella, another for diphtheria, tetanus, and pertussis — have long anchored pediatric programs globally. Yet manufacturers have struggled to develop new combinations without clear guidance, and health officials have lacked reliable tools to evaluate whether adding them to immunization schedules makes sense.
The obstacle is not scientific but evaluative. Standard economic analyses focus narrowly on disease prevention and direct medical costs, missing the real-world friction that combination vaccines reduce. When a parent sees the needle count fall, hesitancy often falls with it, and coverage improves — but conventional frameworks don't measure this. Decision-makers cannot see the full value, and manufacturers lack incentive to invest.
PATH and the World Health Organization set out to close this gap. Through a systematic review of existing evaluations and extensive consultation with immunization experts, health economists, and policy officials, they developed a checklist tool organized around 'value drivers' — the specific attributes that make a combination vaccine more or less attractive than separate shots. Fewer injections, for instance, branches into measurable outcomes: reduced child discomfort, greater parental willingness to complete schedules, and improved coverage in resource-constrained settings.
To bring order to dozens of such drivers, the team created a traffic-light classification system. Green signals high-priority drivers with clear impact and existing measurement methods. Orange and red flag drivers that matter but resist easy quantification — or that are measurable but misaligned with policy priorities. Crucially, the system also reveals research gaps, telling scientists where reliable methods are still needed.
Refined at a June 2025 expert convening and published in the journal Vaccine, the checklist is designed to complement rather than replace existing analyses. PATH and WHO are now applying the framework to specific vaccines in development, with the hope that widespread adoption will give manufacturers clarity, help immunization programs make smarter prioritization decisions, and ultimately ensure that valuable combination vaccines reach the children who need them.
Clinics around the world face a persistent problem: children arriving for routine immunizations must endure multiple needle sticks when a single visit could accomplish the same protection. Two combination vaccines—one protecting against measles and rubella, another against diphtheria, tetanus, and pertussis—have long anchored pediatric immunization programs globally. Yet manufacturers have struggled to develop new combinations without clear direction, and health officials have lacked reliable tools to decide whether adding new combinations to their schedules makes sense.
The bottleneck is not scientific but evaluative. Traditional economic analyses of vaccines focus narrowly on disease prevention and direct medical costs. They miss something crucial: the real-world friction that combination vaccines can reduce. When a parent brings a child in for shots and sees the needle count drop from three to two, hesitancy often drops too. Coverage improves. But standard cost-benefit frameworks don't measure this. They don't capture the relief of fewer injections, the reduced anxiety, the logistical ease for overwhelmed clinics. As a result, decision-makers cannot see the full value of combinations, and manufacturers lack incentive to develop them.
PATH, a global health nonprofit, and the World Health Organization decided to fix this gap. They conducted a systematic review of existing vaccine evaluations, then consulted extensively with immunization experts, health economists, and policy officials. The goal was straightforward: identify what actually matters when assessing a combination vaccine, then create a standardized way to measure it.
What emerged is a checklist tool organized around the concept of "value drivers"—the specific attributes that make a combination vaccine more or less attractive than separate shots. Reducing the number of injections is one driver. But that single benefit branches into measurable outcomes: less discomfort for the child, higher willingness among parents to complete the schedule, improved coverage rates in resource-constrained settings. Each of these can be quantified differently. The team identified dozens of such drivers and their associated metrics, then ranked them using a traffic-light system.
Green lights indicate high priority: value drivers that matter to decision-makers and have clear, measurable impact, with existing methods to evaluate them. Orange and red lights flag drivers that matter but are hard to measure, or that are easy to measure but don't align with policy priorities. This classification reveals research gaps—areas where decision-makers want data but science hasn't yet provided reliable ways to collect it. A driver might be crucial for policy but require new methodologies to assess. Flagging this gap is itself valuable; it tells researchers where to focus.
The checklist was refined at a convening of health economics experts in June 2025, then published in the journal Vaccine. It is not meant to replace existing economic analyses but to complement them, ensuring that when a new combination vaccine is proposed, evaluators consider the full spectrum of its value—not just whether it prevents disease, but whether it actually gets used, whether it reduces burden on clinics and families, whether it frees up resources for other health priorities.
PATH and WHO are now working with partners to apply this framework to specific combination vaccines in development, modeling their potential impact and cost-effectiveness. The hope is that widespread adoption of the checklist will accelerate vaccine development by giving manufacturers clarity on what matters, and will help immunization programs—many stretched thin across competing demands—make smarter decisions about which combinations to prioritize. In a world where health systems must do more with less, a tool that reveals the true value of combinations could be the difference between a vaccine that sits on a shelf and one that reaches the children who need it.
Citas Notables
Traditional economic evaluations often fail to capture the full array of benefits and challenges of combination vaccines, hindering decision-makers from considering their full value— PATH and WHO research findings
La Conversación del Hearth Otra perspectiva de la historia
Why does a checklist matter here? Aren't vaccine evaluations already rigorous?
They are rigorous about disease prevention and cost per case averted. But they're blind to something that actually drives whether people use the vaccine—the experience of getting it. Three injections versus two changes behavior in ways traditional analysis doesn't capture.
So this is about psychology, not epidemiology?
It's about both. If a parent is hesitant and sees fewer needles, coverage goes up. That's epidemiology. But the tool that measures it has to account for human behavior, not just biology.
What does the traffic-light system actually do?
It separates what matters from what's measurable. A value driver might be critically important to policymakers but impossible to quantify with current methods. The red light flags that gap. It tells researchers: here's where you need to innovate.
Who benefits most from this—manufacturers or health programs?
Both, but differently. Manufacturers get clarity on what to build. Programs get a framework to decide what to adopt. The real winner is the child who gets protected faster and with less trauma.
Is this tool ready to use now, or is it still theoretical?
It's published and ready. But the real test comes when programs actually implement it for new vaccines. That's happening now with specific combinations in development.